Oseltamivir Phosphate

Catalog No.S2597 Batch:S259705

Print

Technical Data

Formula

C16H28N2O4.H3PO4
Molecular Weight 410.4 CAS No. 204255-11-8
Solubility (25°C)* In vitro DMSO 82 mg/mL (199.8 mM)
Water 82 mg/mL (199.8 mM)
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Oseltamivir Phosphate(Tamiflu) is a potent and selective inhibitor of the neuraminidase that is essential for replication of influenza A and B viruses, used to prevent influenza.
Targets
Neuraminidase [1]
In vitro

Oseltamivir Phosphate, anti-Neu1 antibodies, and matrix metalloproteinase-9-specific inhibitor blocks Neu1 activity associated with EGF-stimulated TNBC MDA-MB-231 cells[2]. Oseltamivir slows the spread of influenza (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell.
In vivo

Oseltamivir Phosphate monotherapy may be the effective treatment therapy for TNBC(Triple-negative breast cancers)[2]. It is efficacious in treating infections caused by H5N1 and H9N2 influenza viruses in mice[3]. After dosing, the prodrug (Oseltamivir phosphate) is readily absorbed from the gastrointestinal tract and rapidly converted into the active metabolite, OC. In all patient groups, OC has high bioavailability and is systemically distributed to infection sites at concentrations sufficient to inhibit a range of influenza virus neuraminidases[4].

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    MDA-MB-231 cells/MCF-7 cells

  • Concentrations

    500, 600, 700, 800 μg/mL

  • Incubation Time

    24, 48, and 72 h 

  • Method

    Cells are incubated in 96-well plates (5,000 cells/well) and allowed to adhere for 24 hours in 1× DMEM media containing 10% FCS. The media are replaced with fresh DMEM media containing 5% FCS with or without various concentrations of tamoxifen or OP for indicated time periods. Cell viability is tested using WST-1 cell proliferation assay.
Animal Study:

[2]
  • Animal Models

    RAGxCγ double mutant mouse

  • Dosages

    30 or 50 mg/kg

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/9517946/
  • https://pubmed.ncbi.nlm.nih.gov/25525387/
  • https://pubmed.ncbi.nlm.nih.gov/11114412/
  • https://pubmed.ncbi.nlm.nih.gov/20215135/

Customer Product Validation

<p>Nystatin, filipin III, and oseltamivir inhibit the labeling of trophozoites by CTXB and GM1 antibodies. (A) Trophozoites were treated with nystatin (27 μM), filipin III (7.6 μM), and oseltamivir (20 μM) for 30 min before labeling with Alexa Fluor-conjugated CTXB antibody (images a to d) and GM1 antibody (images a′ to d′). Myriocin (27 μM), a sphingolipid inhibitor, was used as a negative control (images e and e′). N, nucleus; PM, plasma membrane; F, flagella; VD, ventral disc. Bars, 5 μm. (B and C) Changes in intensity of control and inhibitor-treated trophozoites. For intensity measurements, cells were randomly selected from 10 to 15 fields from 3 to 5 separate experiments. Approximately 50 cells were considered for each condition and were analyzed using Zeiss Zen 2009 confocal software. One-way ANOVAs were performed to evaluate differences (means ± SDs) between the treatment and control groups. Mean intensities from 3 to 5 separate experiments are shown in panels B and C. Statistical significance was calculated using a one-way ANOVA test, followed by the Tukey (B) and Holm-Šídák (C) methods. *, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant.</p>

, , Infect Immun, 2015, 83(5):2030-42.

Selleck's Oseltamivir Phosphate Has Been Cited by 11 Publications

Rab27a regulates the transport of influenza virus membrane proteins to the plasma membrane [ Nat Commun, 2025, 16(1):6271] PubMed: 40623997
CD26 acts as a host restriction factor to inhibit Influenza A virus (H1N1) infection [ Int J Biol Macromol, 2025, 330(Pt 3):148150] PubMed: 41067348
The critical role of RAGE in severe influenza infection: A target for control of inflammatory response in the disease [ Clin Immunol, 2024, 262:110178] PubMed: 38460892
H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials [ Front Immunol, 2023, 14:1155880] PubMed: 37090729
Differential Production of Type I IFN Determines the Reciprocal Levels of IL-10 and Proinflammatory Cytokines Produced by C57BL/6 and BALB/c Macrophages [ iScience, 2022, 25(4):104088] PubMed: 35402869
Giardial lipid rafts share virulence factors with secreted vesicles and participate in parasitic infection in mice [ Front Cell Infect Microbiol, 2022, 12:974200] PubMed: 36081774
Elevated N-Glycosylation Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells Revealed by Membrane Proteomic and Glycoproteomic Analysis [ Front Pharmacol, 2021, 12:805499] PubMed: 35002739
Antiviral effect of fufang yinhua jiedu (FFYH) granules against influenza A virus through regulating the inflammatory responses by TLR7/MyD88 signaling pathway [ J Ethnopharmacol, 2021, S0378-8741(21)00290-7] PubMed: 33813013
Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein. [ J Cell Mol Med, 2018, 22(3):1826-1839] PubMed: 29193684
The Assembly of GM1 Glycolipid and Cholesterol-Enriched Raft-Like Membrane Microdomains is Important for Giardial Encystation. [De Chatterjee A, et al. Infect Immun, 2015, 10.1128/IAI.03118-14] PubMed: 25733521

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.